InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

Core Insights - InflaRx N.V. announced an oral presentation of its Phase 3 study data for vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting [1][2] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary anti-C5a and anti-C5aR technologies to develop specific inhibitors targeting the complement activation factor C5a and its receptor C5aR [3] - The company's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [3] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [3] Upcoming Presentation Details - The oral presentation titled "Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial" will be presented by Dr. Benjamin Kaffenberger on March 28, 2026, from 2:24 to 2:36 PM MT at the Bellco Theatre 3 [2]